Moleculin Biotech, Inc. - 8-K Filing
Moleculin Biotech secured a Hong Kong patent for its method of reconstituting liposomal Annamycin, extending protection through June 25, 2040. The patent is jointly owned with The University of Texas System and strengthens the company's global IP portfolio ahead of expected Phase 3 clinical data release later in May 2026. (Items: 7.01 Regulation FD Disclosure On May 8, 2026, Moleculin Biotech, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $MBRX